
Dmitriy Sonkin, Ph.D.
Biography
Dr. Sonkin is a computational biologist in the Computational and Systems Biology Branch of the Biometric Research Program (BRP/DCTD). Dr. Sonkin research interests include cancer diagnosis and treatment, target and biomarker discovery, genomic characterization of cancer models, variants classification and annotation. Dr. Sonkin is co-chair of ClinGen Somatic/Germline working group, and ClinGen MAPK/ERK pathway Somatic Cancer Variant Curation Expert Panel, and member of ClinGen Somatic Cancer Variant Interpretation Committee (CVI-C). Dr. Sonkin is a senior corresponding author on the ClinGen/CGC/VICC SOP for the classification of oncogenicity of somatic variants.
Prior to joining NCI/DCTD in 2015 Dr. Sonkin worked at the Novartis Institutes for BioMedical Research (NIBR) located in Cambridge Massachusetts. Prior to joining NIBR in 2008 he worked at Harvard Medical School Partners Center for Genetics and Genomics (HPCGG) also located in Cambridge Massachusetts.
Selected Publications
- Rachel Karchin, Predrag Radivojac, Anne O’Donnell-Luria, Marc S Greenblatt, Michael Y Tolstorukov, Dmitriy Sonkin: Improving transparency of computational tools for variant effect prediction. Nature Genetics, 2024; doi: 10.1038/s41588-024-01821-8
- Peter Horak, Malachi Griffith, Arpad M. Danos, Beth A. Pitel, Subha Madhavan, Xuelu Liu, Cynthia Chow, Heather Williams, Leigh Carmody, Lisa Barrow-Laing, Damian Rieke, Simon Kreutzfeldt, Albrecht Stenzinger, David Tamborero, Manuela Benary, Padma Sheila Rajagopal, Cristiane M. Ida, Harry Lesmana, Laveniya Satgunaseelan, Jason D. Merker, Michael Y. Tolstorukov, Paulo Vidal Campregher, Jeremy L. Warner, Shruti Rao, Maya Natesan, Haolin Shen, Jeffrey Venstrom, Somak Roy, Kayoko Tao, Rashmi Kanagal-Shamanna, Xinjie Xu, Deborah I. Ritter, Kym Pagel, Kilannin Krysiak, Adrian Dubuc, Yassmine M. Akkari, Xuan Shirley Li, Jennifer Lee, Ian King, Gordana Raca, Alex H. Wagner, Marylin M. Li, Sharon E. Plon, Shashikant Kulkarni, Obi L. Griffith, Debyani Chakravarty, Dmitriy Sonkin: Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genetics in Medicine, 2022; doi: 10.1016/j.gim.2022.01.001
- Alida Palmisano, Suleyman Vural, Yingdong Zhao, Dmitriy Sonkin: MutSpliceDB: A database of splice sites variants with RNA-seq based evidence on effects on splicing. Human Mutation, 2021; doi: 10.1002/humu.24185
- Mahmoud Ghandi, Franklin W Huang, Judit Jane-Valbuena, Gregory V Kryukov, Christopher C Lo, E Robert McDonald, Jordi Barretina, Ellen T Gelfand, Craig M Bielski, Haoxin Li, Kevin Hu, Alexander Y Andreev-Drakhlin, Jaegil Kim, Julian M Hess, Brian J Haas, Francois Aguet, Barbara A Weir, Michael V Rothberg, Brenton R Paolella, Michael S Lawrence, Rehan Akbani, Yiling Lu, Hong L Tiv, Prafulla C Gokhale, Antoine De Weck, Ali Amin Mansour, Coyin Oh, Juliann Shih, Kevin Hadi, Yanay Rosen, Jonathan Bistline, Kavitha Venkatesan, Anupama Reddy, Dmitriy Sonkin, Manway Liu, Joseph Lehar, Joshua M Korn, Dale A Porter, Michael D Jones, Javad Golji, Giordano Caponigro, Jordan E Taylor, Caitlin M Dunning, Amanda L Creech, Allison C Warren, James M McFarland, Mahdi Zamanighomi, Audrey Kauffmann, Nicolas Stransky, Marcin Imielinski, Yosef E Maruvka, Andrew D Cherniack, Aviad Tsherniak, Francisca Vazquez, Jacob D Jaffe, Andrew A Lane, David M Weinstock, Cory M Johannessen, Michael P Morrissey, Frank Stegmeier, Robert Schlegel, William C Hahn, Gad Getz, Gordon B Mills, Jesse S Boehm, Todd R Golub, Levi A Garraway, William R Sellers: Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature, 2019; doi: 10.1038/s41586-019-1186-3
- Dmitriy Sonkin: Expression signature based on TP53 target genes does not predict response to TP53-MDM2 inhibitor in wild type TP53 tumors. eLife, Oct 22, 2015; doi: 10.7554/eLife.10279
For the complete publications record, see Google Scholar full list of publications.